<DOC>
	<DOCNO>NCT01684865</DOCNO>
	<brief_summary>This prospective observational study evaluate safety efficacy first-line rituximab maintenance therapy participant follicular non-Hodgkin 's lymphoma . Participants initiate rituximab maintenance therapy accord standard care line current summary product characteristic follow maximum 3 year disease progression occur .</brief_summary>
	<brief_title>An Observational Study First-Line Maintenance Rituximab ( MabThera/Rituxan ) Participants With Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histological diagnosis follicular nonHodgkin 's lymphoma Complete partial response firstline induction therapy chemotherapy rituximab Participants receive firstline rituximab maintenance treatment follicular nonHodgkin 's lymphoma accord local label Pregnant lactate woman Receipt investigational drug within 30 day prior initiation observational drug Any medical psychological alteration , criterion investigator , jeopardize capacity participant grant inform consent Central nervous system involvement Hepatitis B C virus infection human immuno deficiency infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>